The Non-Malignant Haematology Specialty Group is
one of 23 Specialty Groups which provide national
networks of topic-specific expertise. These groups
are key to the success of the CCRN. They work at both
national and local levels to ensure the successful
delivery of research within their specialties. This
means ensuring that studies are delivered to target
and on time.
The speciality of non-malignant haematology covers at a broad range of blood disorders which affect people of all ages from young to old as well as those from a broad range of ethnic backgrounds.
Managing these disorders can be difficult and treatment is sometimes lifelong requiring the use of blood products, clotting factors or drugs to thin the blood.
Our remit, as a group, is to improve the care of patients with non-malignant haematological disorders by working with patients, doctors and the life sciences industry to develop and deliver new and improved therapies. We aim to broaden the access of patients with non-malignant haematological disorders to clinical trials by increasing the number of hospitals that can give patients the opportunity to participate in these studies.
The group supports and promotes research in:
Research studies of haematological cancers are supported by the NIHR Cancer Research Network (NCRN) and the Non-Malignant Haematology Specialty Group works alongside the NCRN to support these studies.
What we do
How we work with the life-sciences industry How to get involved